Barbara Ann Karmanos Cancer Institute
A Detroit-based cancer research, treatment, education, and clinical-trial network affiliated with Wayne State University School of Medicine.
Last updated August 22, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
The Barbara Ann Karmanos Cancer Institute, commonly known as Karmanos Cancer Institute, is a nonprofit cancer research and treatment organization headquartered in Detroit, Michigan. It combines patient care, laboratory and translational research, cancer education, prevention-oriented work, and clinical trials. The institute is affiliated with Wayne State University School of Medicine and operates a network of treatment locations in Michigan. Its stated vision is a world free of cancer, while its mission centers on advancing cancer care, research, and education through courage, commitment, and compassion. Karmanos traces its institutional origins to the Detroit Institute for Cancer Research, established in 1943. The organization was incorporated as a nonprofit in 1949 and later developed into the Michigan Cancer Foundation. During that evolution, the organization encompassed the Meyer L. Prentis Comprehensive Cancer Center of Metropolitan Detroit as well as cancer programs connected with the Detroit Medical Center and Wayne State University. This history placed Karmanos within Detroit's broader academic-medicine and hospital ecosystem rather than positioning it solely as a standalone outpatient provider. In 1995, the cancer center adopted the Karmanos name in honor of Barbara Ann Karmanos, who died from breast cancer at the age of 46. The naming linked the institute's identity with cancer advocacy, research, and the personal experience of a prominent Michigan family. Peter Karmanos Jr., Barbara Ann Karmanos's husband, was formerly chairman and chief executive officer of Compuware Corporation and became associated with the institute's philanthropic development. Karmanos provides care across multiple cancer specialties and treatment settings. Its network model gives patients access to oncology physicians, diagnostic and therapeutic services, supportive care, and clinical research through locations beyond its Detroit base. The institute is also known for a substantial clinical-trials operation, including early-phase research. Reference material describes access to more than 250 investigational treatments, approximately 800 cancer-focused scientific investigations and clinical trials annually, and participation in the National Cancer Institute's Early Therapeutics Clinical Trials Network through a Phase 1 program. A strategic agreement with McLaren Health Care Corporation, signed in October 2013 and finalized in January 2014, created a large Michigan cancer research and provider network. The arrangement expanded the geographic reach of Karmanos-associated cancer services and connected the institute's academic and research capabilities with McLaren's healthcare infrastructure. Karmanos remains one of the National Cancer Institute-designated comprehensive cancer centers in the United States and is described in the reference material as one of 57 such centers. In 2018, the organization reported approximately 1,000 employees, including about 300 physicians and 100 researchers, and treatment of roughly 12,000 patients annually. Those figures are historical rather than current operating statistics. The institute's public identity is therefore built around comprehensive oncology care, academic research, access to clinical trials, and a statewide provider network. Its recognition by the Women's Choice Award, including cancer-care and patient-experience distinctions in several years, reflects external attention to its care and research services. Current operations, staffing, locations, and leadership may have changed since the cited reference material and should be verified against the institute's present website.
History
Karmanos Cancer Institute originated in Detroit in 1943 as the Detroit Institute for Cancer Research. The organization was incorporated as a nonprofit in 1949, establishing the legal and institutional foundation for a cancer-focused research and care organization. It subsequently became known as the Michigan Cancer Foundation, a broader organization that included the Meyer L. Prentis Comprehensive Cancer Center of Metropolitan Detroit and cancer programs associated with the Detroit Medical Center and Wayne State University. The institution's development reflected the increasing integration of cancer research, specialist treatment, university medicine, and hospital services. Its connection with Wayne State University School of Medicine gave it an academic platform, while its relationships with Detroit-area hospitals allowed cancer programs to operate across clinical settings. Over time, the organization evolved from a research-focused Detroit nonprofit into a comprehensive cancer center with patient-care, research, education, and clinical-trial functions. In 1995, the cancer center was renamed in honor of Barbara Ann Karmanos, who had died of breast cancer at age 46. The name commemorated a personal experience with cancer and became the public identity of the institution. Peter Karmanos Jr., her husband and a former chairman and chief executive officer of Compuware Corporation, was associated with the institute's philanthropic and civic profile. A major organizational turning point came in 2013, when Karmanos Cancer Institute and McLaren Health Care Corporation announced an agreement to create a larger cancer research and provider network in Michigan. The agreement was signed on October 30, 2013, and finalized in January 2014. The resulting relationship broadened the network's geographic reach and linked Karmanos's academic cancer expertise with McLaren's healthcare delivery system. Karmanos continued to operate as a cancer institute and provider network centered in Detroit while serving patients at multiple locations. By the late 2010s, Karmanos was described as having 18 treatment locations and as one of the National Cancer Institute-designated comprehensive cancer centers in the United States. Its clinical research program was characterized as one of the largest in the country, with access to more than 250 treatments and roughly 800 cancer-specific scientific investigations and clinical trials each year. The organization also operated a Phase 1 program and participated as a site in the National Cancer Institute's Early Therapeutics Clinical Trials Network. In 2018, reference material described an organization with approximately 1,000 employees, including 300 physicians and 100 researchers, treating about 12,000 patients per year. The same material cited a historical operating budget of $260 million. These figures describe the institute at that time and should not be treated as current without updated institutional reporting. Karmanos also received recognition from the Women's Choice Award, including cancer-care and research recognition in 2018, earlier cancer-care recognition in several years, and a patient-experience award in 2017. Today, the institute's identity rests on the combination of comprehensive oncology care, academic research, clinical-trial access, and a networked Michigan delivery model. Its Detroit headquarters and Wayne State affiliation remain central to its profile, while its relationship with McLaren has supported a broader provider network. Current facilities, leadership, staffing, and programs require confirmation from the institute's current official materials.
- 2018
Women's Choice Award cancer-care recognition
[1]The institute was recognized as one of America's Best Hospitals for Cancer Care and Research by the Women's Choice Award.
- 2017
Women's Choice Award for patient experience
[1]Karmanos received a Women's Choice Award recognizing patient experience.
- 2014
McLaren network agreement finalized
[1]The Karmanos-McLaren arrangement was finalized, expanding the connected cancer-care and research network.
- 2013
Agreement with McLaren announced
[1]Karmanos and McLaren Health Care announced an agreement to create a large Michigan cancer research and provider network.
- 1995
Cancer center renamed for Barbara Ann Karmanos
[1]The cancer center adopted the Barbara Ann Karmanos name in memory of Barbara Ann Karmanos, who died from breast cancer at age 46.
- 1949
Nonprofit registration
[1]The organization was registered as a nonprofit institution.
- 1943
Detroit Institute for Cancer Research established
[1]The institutional predecessor of Karmanos Cancer Institute began operating in Detroit as the Detroit Institute for Cancer Research.
Products and positioning
An academic, research-intensive comprehensive cancer center that combines advanced oncology treatment, clinical trials, cancer science, and a Michigan-wide care network.
Oncology treatment
Comprehensive cancer care
Karmanos provides multidisciplinary cancer diagnosis and treatment through its Detroit base and affiliated treatment locations. Its clinical scope includes specialist oncology services and coordinated care intended for patients with a broad range of cancers. The institute's comprehensive-center model connects direct treatment with research, education, and access to investigational therapies.
Clinical research
Clinical trials and early therapeutics
The institute operates a substantial clinical-trials program, including a Phase 1 program and participation in the National Cancer Institute's Early Therapeutics Clinical Trials Network. Reference material describes access to more than 250 treatments and approximately 800 cancer-specific investigations and clinical trials each year. These programs give eligible patients access to investigational approaches while supporting the development of new cancer therapies.
Research and academic medicine
Cancer research and education
Karmanos combines laboratory, clinical, and translational cancer research with professional and patient education. Its academic relationship with Wayne State University School of Medicine supports the connection between scientific investigation, physician training, and cancer treatment. The institute's research identity is central to its designation as a comprehensive cancer center.
Healthcare network · 2014
Michigan cancer provider network
Through its relationship with McLaren Health Care, Karmanos is associated with a network of cancer treatment locations across Michigan. The network extends access beyond the Detroit headquarters and combines Karmanos's cancer research and specialty-care capabilities with McLaren's broader healthcare delivery infrastructure.
Brand decisions
2013
Create a combined Karmanos-McLaren cancer networkM&ABackground
Karmanos sought to expand the reach of its cancer research and provider activities through a relationship with McLaren Health Care Corporation.
Action taken
The organizations signed an agreement on October 30, 2013, to create a large Michigan cancer research and treatment network.
Aftermath
The agreement was finalized in January 2014 and became a major structural development in Karmanos's statewide network model.
Recent events
- 2018
Karmanos recognized by the Women's Choice Award for cancer care and research[1]
Other
The institute was listed among America's Best Hospitals for Cancer Care and Research by the Women's Choice Award.
- 2017
Karmanos receives Women's Choice Award patient-experience recognition[1]
Other
The institute received a Women's Choice Award for patient experience, alongside its cancer-care recognition.
- 2014
Karmanos-McLaren cancer network agreement finalized[1]
M&A
The agreement between Karmanos and McLaren was completed, establishing the expanded cancer research and treatment network.
- 2013
Karmanos Cancer Institute and McLaren Health Care form Michigan cancer network[1]
M&A
Karmanos Cancer Institute and McLaren Health Care Corporation signed an agreement intended to combine cancer research and provider capabilities across Michigan.
Sources3 sources
Cite this profile: Cite the canonical profile. /brand-wiki/barbara-ann-karmanos-cancer-institute · Editorial policy · How profiles are compiled